Product
parsaclisib
Aliases
INCB050465
6 clinical trials
10 indications
Indication
Chronic Lymphocytic LeukemiaIndication
Non-Hodgkin LymphomaIndication
lymphomaIndication
Non-Hodgkin lymphomaIndication
Diffuse Large B-cell LymphomaIndication
MyelofibrosisIndication
Primary MyelofibrosisIndication
Post Polycythemia Vera MyelofibrosisIndication
Follicular LymphomaClinical trial
A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With MyelofibrosisStatus: Active (not recruiting), Estimated PCD: 2023-08-03
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to RuxolitinibStatus: Active (not recruiting), Estimated PCD: 2023-08-16
Clinical trial
A Phase Ib/III Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular LymphomaStatus: Withdrawn, Estimated PCD: 2029-08-31